BEOVU
PeakmAbBLAINTRAVITREALINJECTABLEPriority Review
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
BEOVU by Novartis is inhibitor. First approved in 2019.
Drug data last refreshed 22h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEOVU (brolucizumab) is a monoclonal antibody administered via intravitreal injection for the treatment of neovascular age-related macular degeneration (AMD). It targets vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth in the retina. The drug represents an alternative to other anti-VEGF therapies with a potentially longer durability profile.
$0.602MPart D
PeakBEOVU is in peak commercial phase with modest Medicare utilization, suggesting a mature but focused franchise requiring specialized medical and sales expertise in ophthalmology.
Mechanism of Action
inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF 110 , VEGF 121 , and VEGF 165 ), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
Started Sep 2022
222 enrolled
Diabetic Macular Edema
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
Started May 2022
2,079 enrolled
Neovascular (Wet) Age-related Macular Degeneration
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Started Nov 2020
572 enrolled
Neovascular Age-related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)
Worked on BEOVU at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.